Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICT: Nal-IRI in 2nd-line Pancreatic Cancer
NCT03468335Phase 3Completed
- Sponsor
- AIO-Studien
- Start
- Mar 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan liposome injection in pancreatic ductal adenocarcinoma (PDAC), sponsored by AIO-Studien. Started Mar 2018; status: completed.
02
Drugs
irinotecan liposome injection
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03468335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468335.